What's new

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Mar 17, 2025 - 15:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Read More

Tags:

Previous Article

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

Next Article

PepsiCo to acquire poppi

Related Posts

EMEA-003484-PIP01-23

EMEA-003484-PIP01-23

Mar 4, 2025  0

Quarterly System Demo – Q1 2025, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 26 March 2025, 09:00 (CET) to 26 March 2025, 11:30 (CET)

Quarterly System Demo – Q1 2025, Online, European Medic...

Feb 13, 2025  0

Clinical Trial Information System (CTIS) - Sponsor hand...

Feb 19, 2025  0